Alto Neuroscience, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 22.6 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 886.87M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson’s disease for patients with Parkinson’s disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.
Details
| Name | Alto Neuroscience, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 68 |
| Founded | 2019 |
| Ipo Date | 2024-02-02 |
| Ceo | Amit Etkin |
| Country | United States |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 16.00 |
| Isin | US02157Q1094 |
| Cusip | 02157Q109 |
| Cik | 1999480 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Amit Etkin M.D., Ph.D. | Founder, Chief Executive Officer and Chairman of the Board |
| Nicholas C. Smith | Chief Financial Officer and President |
| Michael C. Hanley M.B.A. | Chief Operating Officer |
| Dan Segal B.Sc. (Hons), BCom, CA, MSc | Co-Founder and Strategic Advisor |
| Erin R. McQuade J.D. | General Counsel, Chief Administrative Officer and Corporate Secretary |
| Adam Savitz M.D., Ph.D. | Chief Medical Officer |
| Jessica Powell | Chief Development Officer |
Contact
| Address | 650 Castro Street, Suite 450, Mountain View, California 94041, United States |
| Phone | 650 200 0412 |
| Website | https://www.altoneuroscience.com |